Pfizer and AbbVie Announce Leadership Changes in Global R&D Divisions
In significant executive reshuffling, Pfizer Inc. (NYSE: PFE) and AbbVie (NYSE: ABBV) have both announced...
AbbVie
Genmab and AbbVie’s Epcoritamab Earns FDA Accelerated Approval for Follicular Lymphoma
Genmab A/S (NASDAQ: GMAB), a Danish biotechnology company, and its co-development partner AbbVie (NYSE: ABBV),...
AbbVie Bolsters Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition
AbbVie (NYSE: ABBV), a major U.S. pharmaceutical company, has announced the acquisition of Celsius Therapeutics...
AbbVie’s Skyrizi Secures FDA Approval for Ulcerative Colitis, Expands Treatment Portfolio
AbbVie (NYSE: ABBV) has announced that the U.S. Food and Drug Administration (FDA) has approved...
AbbVie Warns Shareholders Against Tutanota’s Unsolicited Mini-Tender Offer
Private investment firm Tutanota has launched an unsolicited mini-tender offer to acquire up to 250,000...
AbbVie Strikes Deal with FutureGen for Global Rights to Next-Gen TL1A Antibody FG-M701
AbbVie (NYSE: ABBV), a biopharmaceutical giant based in the US, has announced a licensing agreement...
AbbVie-Calico Partnership Advances with FDA Approval for Fosigotifator Trial in Rare Brain Disorder
The US Food and Drug Administration (FDA) has welcomed an experimental therapy, fosigotifator, developed by...
AbbVie’s Telisotuzumab Vedotin Earns Breakthrough Therapy Designation in China for c-Met Positive NSCLC
AbbVie Inc. (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced that...
Allergan Aesthetics’ Botox Secures New Indication for Masseter Muscle Protrusion in China
Allergan Aesthetics, a division of AbbVie (NYSE: ABBV), has announced that it has received approval...
AbbVie and Gilgamesh Pharmaceuticals Join Forces to Develop Psychiatric Disorder Therapies
AbbVie (NYSE: ABBV) has announced a partnership with US-based Gilgamesh Pharmaceuticals to develop a portfolio...
AbbVie’s Rinvoq Outperforms Sanofi’s Dupixent in Moderate-to-Severe Atopic Dermatitis Trial
AbbVie (NYSE: ABBV) has announced positive results from a head-to-head Phase IIIb/IV clinical trial comparing...
European Commission Approves Pfizer’s Antibiotic Emblaveo for Multiple Indications
The European Commission (EC) has granted approval for Pfizer’s (NYSE: PFE) antibiotic Emblaveo (aztreonam +...
AbbVie’s Rinvoq Meets Main Goal in Late-Stage Giant Cell Arteritis Trial
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, has announced that a late-stage clinical trial...
AbbVie Partners with Medincell for Development of Long-Acting Injectable Therapies
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, has entered into a partnership with France-based...
AbbVie’s Aquipta/Qulipta Shows Promise in Migraine Prevention Trial
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, last week released interim results from a...
Allergan Aesthetics Launches SKINMEDICA in China, Targeting Booming Skincare Market
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced the market launch of its...
AbbVie Acquires Landos Biopharma to Boost Autoimmune Disease Pipeline
AbbVie (NYSE: ABBV) has announced its acquisition of Landos Biopharma (NASDAQ: LABP), a biopharmaceutical company...
CNIPA Invalidates AbbVie Patents, Setting New Precedent for Pharmaceutical Disclosure
The China National Intellectual Property Administration (CNIPA)’s Patent Re-examination Board (PRB) has reportedly invalidated two...
AbbVie Partners with OSE Immunotherapeutics to Develop First-in-Class Immunotherapy OSE-230
AbbVie (NYSE: ABBV) has entered into a strategic partnership with France-based OSE Immunotherapeutics (EPA: OSE)...
Alvotech Scores FDA Nod for Interchangeable High-Concentration Biosimilar to Humira
The US Food and Drug Administration (FDA) has granted approval to Iceland-based Alvotech’s (NASDAQ: ALVO)...